

Chemotherapy Protocols

LUNG CANCER

Protocol	Hospital using the Protocol
Small Cell Lung Cancer	
Carboplatin & Etoposide	RSCH, SASH, FPH, ASH
CAV	RSCH, SASH, FPH, ASH
Cisplatin & Etoposide	RSCH, FPH, ASH
Topotecan (oral)	RSCH, FPH, ASH
Non Small Cell Lung Cancer (NSCLC)	
Afatinib	RSCH, FPH, ASH
Alectinib	RSCH, FPH, ASH
Ceritinib	RSCH, FPH, ASH
Crizotinib	RSCH, FPH, ASH
Docetaxel +/- Nintedanib	RSCH, FPH, ASH
Erlotinib	RSCH, FPH, ASH
Gefitinib	RSCH, FPH, ASH
Gemcitabine & Carboplatin	RSCH, SASH, FPH, ASH
Gemcitabine & Cisplatin	RSCH, FPH, ASH
Nivolumab	RSCH, FPH, ASH
Osimertinib	RSCH, FPH, ASH
Paclitaxel & Carboplatin	RSCH, FPH, ASH
Paclitaxel weekly, carboplatin weekly & RT	RSCH
Pembrolizumab (stored in Skin section)	RSCH, FPH, ASH
Pemetrexed single agent	RSCH, FPH, ASH
Vinorelbine	RSCH, SASH, FPH, ASH
Vinorelbine & Cisplatin	RSCH, FPH, ASH
Vinorelbine, Cisplatin & RT	RSCH, FPH, ASH
Mesothelioma & NSCLC	
Pemetrexed & Carboplatin	RSCH, FPH, ASH
Pemetrexed & Cisplatin	RSCH, FPH, ASH

RSCH = Royal Surrey County Hospital;
FPH = Frimley Park Hospital;

SASH = Surrey and Sussex Healthcare Trust;
ASH = Ashford Hospital

NB. The following reference sources were used routinely and are not individually referenced on each protocol:
Summary of Product Characteristics
Dose Adjustments for Cytotoxics in Renal and Hepatic Impairment, 2009 update, produced by UCLH NHS Foundation Trust

Please note: the "Main Toxicities" section includes only predictable and/or important side effects. For more detailed information on side effects, please seek further literature.

Reason for Update: Alectinib, Ceritinib and Nivolumab added	Prepared by: S Taylor
Version: 19	Date: December 2017
Supersedes: Version 18	